||Clofibric acid is an antilipemic agent that is the biologically active metabolite of CLOFIBRATE.
||Seratrodast (INN), a thromboxane A2 (TXA2) receptor (TP receptor) antagonist, is mainly used in the therapy of asthma. It was the first TP receptor antagonist developed as an anti-asthmatic drug and attained marketing qualification in Japan in 1997.
||Pioglitazone is an insulin sensitizing agent and thiazolidinedione that is indicated for the treatment of type 2 diabetes. Pioglitazone has been linked to rare instances of acute liver injury.
||Pioglitazone Hydrochloride is the hydrochloride salt of an orally-active thiazolidinedione with antidiabetic properties and potential antineoplastic activity.
||Rosiglitazone is an insulin sensitizing agent and thiazolidinedione that is indicated for the treatment of type 2 diabetes. Rosiglitazone has been linked to rare instances of acute liver injury.
||Dexibuprofen, S(+)-ibuprofen, is a non-steroidal anti-inflammatory drug (NSAID), inhibiting cyclooxygenase (COX).
||Mesalamine is an anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE.
||Triflusal is a 2-acetoxy-4-trifluoromethylbenzoic acid and it is an aspirin chemically-related molecule but not a derivative.
||Bezafibrate is an antilipemic agent that lowers CHOLESTEROL and TRIGLYCERIDES. It decreases LOW-DENSITY LIPOPROTEINS and increases HIGH-DENSITY LIPOPROTEINS.
||Repaglinide is a benzoic acid derivative that stimulates insulin secretion from the pancreas and is used in the therapy of type 2 diabetes. Repaglinide has been linked to rare instances of clinically apparent acute liver injury.
||Fenofibrate is a peroxisome proliferator receptor alpha agonist. Fenofibrate is a synthetic phenoxy-isobutyric acid derivate and prodrug with antihyperlipidemic activity.
||Daidzein is an isoflavone extract from soy, which is an inactive analog of the tyrosine kinase inhibitor genistein. It has antioxidant and phytoestrogenic properties.
||Ciprofibrate is a fibrate derivative with antilipidemic activity.
||Clofibrate is an aryloxyisobutyric acid derivate with antihyperlipidemic activity.
||Fenofibric Acid is the active form of fenofibrate, a synthetic phenoxy-isobutyric acid derivate with antihyperlipidemic activity.
||Gemfibrozil interacts with peroxisome proliferator-activated receptors (PPARalpha) resulting in PPARalpha-mediated stimulation of fatty acid oxidation and an increase in lipoprotein lipase (LPL) synthesis. Gemfibrozil is a fibric acid derivative with hypolipidemic effects. This enhances triglyceride
||Glipizide is a short-acting, second-generation sulfonylurea with hypoglycemic activity.
||Rosiglitazone Maleate is the maleate salt of rosiglitazone, an orally-active thiazolidinedione with antidiabetic properties and potential antineoplastic activity.
||Nateglinide is an oral hypoglycemic agent and amino acid derivative that stimulates insulin secretion from the pancreas and is used in the therapy of type 2 diabetes. Nateglinide has been linked to rare instances of clinically apparent acute liver injury.
||JW 55 is an effective and selective β-catenin signaling pathway inhibitor, works by inhibition of the PARP domain of tankyrase 1 and tankyrase 2 (TNKS1/2).
||XAV-939 shows the selective inhibition against Wnt/β-catenin-mediated transcription by tankyrase1/2 inhibition (IC50: 11/4 nM in cell-free assays), regulates axin levels and does not affect TGF-β, NF-κB or CRE.
||GSK3787 is a specific and irreversible PPARδ inhibitor（pIC50= 6.6）.
||LB-100 is a water soluble protein phosphatase 2A (PP2A) inhibitor. Phase 1.
||GW9662 is a specific PPARγ antagonist (IC50: 3.3 nM, in a cell-free assay), with 100 to 1000-fold functional selectivity for PPARγ than PPARα/δ in cells.
||Pirinixic Acid is a synthetic thiacetic acid derivative used in biomedical research, carcinogenic Pirinixic acid is a peroxisome proliferator that activates specific peroxisome proliferator-activated receptors (PPAR).
||Ramatroban (BAY u3405) is a thromboxane A(2) (TxA(2)) antagonist marketed for allergic rhinitis. It has been used in trials studying the treatment of Asthma.
||FH535, a Wnt/β-catenin signaling and PPAR inhibitor, exhibits anti-tumor activities.
||GSK0660 is an antagonist and inverse agonist of PPARβ/δ.
||Extracted from whole herb of Gynostemsma pentaphyllum(Thunb.)Mak.;Store the product in sealed, cool and dry condition.
||Magnolol is a dual agonist of RXRα( EC50=10.4 µM) and PPARγ(EC50=17.7 µM). It blocks TNF-α-induced NF-KB activation.
||WIKI4 is a potent inhibitor of Wnt/β-catenin signaling and tankyrase 2 (TNKS2).
||Abietic Acid is the primary component of resin acid isolated from rosin.
||Troglitazone is a PPARγ agonist with anti-inflammatory and anti-tumor activity.
||NVP-TNKS656 is a highly potent, selective, and orally active TNKS2 inhibitor.
||XMD8-87 is a TNK2 inhibitor with activity in the inhibition of TNK2 phosphorylation. XMD8-87 and XMD16-5 potently inhibit phosphorylation of TNK2 truncation mutations found in solid tumor types.
||XMD16-5 is a TNK2 inhibitor. TNK2 genomic amplification has been associated with late-stage or metastatic lung and prostate Ys. Overexpression of TNK2 promoted metastasis in a mouse model of breast Y. TNK2 signaling is disrupted in breast, prostate and gastrointestinal tumors.
||Protopanaxatriol, a major ginseng constituent, is a novel PPARγ antagonist.
||GW501516 is a effective and highly specifc PPARβ/δ agonist (EC50: 1 nM), with 1000-fold selectivity over hPPARα/γ.
||GW0742 (GW610742) is an effective and specific PPARδ agonist (EC50: 1nM/1.1μM/2 μM, for human PPARδ/α/γ).
||Rosiglitazone HCl is a blood glucose-lowering drugs, stimulating insulin secretion by binding to the PPAR receptors in fat cells.
||T0070907(IC50=1 nM) ，an effective and specific PPARγ inhibitor, with the >800-fold selectivity over PPARα and PPARδ.
||AZ6102 is a potent TNKS1/2 inhibitor that has 100-fold selectivity against other PARP family enzymes and shows IC50 of 5 nM for Wnt pathway inhibition in DLD-1 cells.
||Palmitoylethanolamide(PEA) ，an endogenous fatty acid amide， activates PPAR-α selectively in vitro (EC50=3.1±0.4 μM）.
||SR-18292 is a PPAR gamma coactivator-1α (PGC-1α) inhibitor, which increases PGC-1α acetylation, suppresses gluconeogenic gene expression and reduces glucose production in hepatocytes.
||Elafibranor is an agonist of the peroxisome proliferator-activated receptor-α (PPAR-α) and peroxisome proliferator-activated receptor-δ (PPAR-δ) with EC50 values of 45 and 175 nM, respectively.
||LB-100 is a water-soluble protein phosphatase 2A (PP2A) inhibitor (IC50: 0.85/3.87 μM, in BxPc-3/Panc-1 cells).